Unknown

Dataset Information

0

Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.


ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.

SUBMITTER: Foss FM 

PROVIDER: S-EPMC7316063 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.

Foss Francine M FM   Rubinowitz Ami A   Landry Marie L ML   Isufi Iris I   Gowda Lohith L   Seropian Stuart S   Perreault Sarah S   Shenoi Sheela V SV  

Clinical lymphoma, myeloma & leukemia 20200625 11


Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia. ...[more]

Similar Datasets

| S-EPMC4925499 | biostudies-other
| S-EPMC8477622 | biostudies-literature
| S-EPMC8931584 | biostudies-literature
| S-EPMC5459682 | biostudies-literature
| S-EPMC8689898 | biostudies-literature
| S-EPMC6706301 | biostudies-literature
| S-EPMC4408224 | biostudies-literature
| S-EPMC8280601 | biostudies-literature
| S-EPMC4852556 | biostudies-literature
| S-EPMC5498945 | biostudies-other